Form 8-K - Current report:
SEC Accession No. 0000950170-24-124067
Filing Date
2024-11-08
Accepted
2024-11-08 16:05:21
Documents
12
Period of Report
2024-11-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kpti-20241105.htm   iXBRL 8-K 61768
2 EX-10.1 kpti-ex10_1.htm EX-10.1 79755
  Complete submission text file 0000950170-24-124067.txt   275644

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kpti-20241105.xsd EX-101.SCH 30859
14 EXTRACTED XBRL INSTANCE DOCUMENT kpti-20241105_htm.xml XML 4700
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 241440481
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)